X0306 4 2022-11-21 1 0001337553 AERIE PHARMACEUTICALS INC AERI 0001892279 Calabrese Jeffrey C/O AERIE PHARMACEUTICALS, INC. 4301 EMPEROR BLVD., SUITE 400 DURHAM NC 27703 0 1 0 0 Vice President of Finance Common Stock 2022-11-21 4 D 0 18585 15.25 D 0 D Stock Option (right to buy) 11.02 2022-11-21 4 D 0 6257 4.23 D 2031-11-01 Common Stock 6257 0 D Stock Option (right to buy) 8.36 2022-11-21 4 D 0 20774 6.89 D 2032-07-01 Common Stock 20774 0 D Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes. Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of August 22, 2022, by and among Aerie Pharmaceuticals, Inc. (the "Company"), Alcon Research, LLC (the "Parent"), and Lyon Merger Sub, Inc., a copy of which is filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on August 23, 2022, pursuant to which the Company became a wholly owned subsidiary of Parent on November 21, 2022 (the "Effective Time"). /s/ John W. LaRocca, Attorney-in-Fact for Jeffrey Calabrese 2022-11-21